Logo image of IBRX

IMMUNITYBIO INC (IBRX) Stock Fundamental Analysis

NASDAQ:IBRX - Nasdaq - US45256X1037 - Common Stock - Currency: USD

2.69  0 (0%)

After market: 2.7 +0.01 (+0.37%)

Fundamental Rating

3

We assign a fundamental rating of 3 out of 10 to IBRX. IBRX was compared to 568 industry peers in the Biotechnology industry. IBRX may be in some trouble as it scores bad on both profitability and health. IBRX shows excellent growth, but is valued quite expensive already.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year IBRX has reported negative net income.
In the past year IBRX has reported a negative cash flow from operations.
IBRX had negative earnings in each of the past 5 years.
In the past 5 years IBRX always reported negative operating cash flow.
IBRX Yearly Net Income VS EBIT VS OCF VS FCFIBRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -100M -200M -300M -400M -500M

1.2 Ratios

Looking at the Return On Assets, with a value of -108.00%, IBRX is doing worse than 78.35% of the companies in the same industry.
Industry RankSector Rank
ROA -108%
ROE N/A
ROIC N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
IBRX Yearly ROA, ROE, ROICIBRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100

1.3 Margins

IBRX's Gross Margin of 100.00% is amongst the best of the industry. IBRX outperforms 98.77% of its industry peers.
IBRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 100%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
IBRX Yearly Profit, Operating, Gross MarginsIBRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K

More info and screens

2

2. Health

2.1 Basic Checks

IBRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
IBRX has more shares outstanding than it did 1 year ago.
IBRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, IBRX has a worse debt to assets ratio.
IBRX Yearly Shares OutstandingIBRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M
IBRX Yearly Total Debt VS Total AssetsIBRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 200M 400M 600M 800M

2.2 Solvency

IBRX has an Altman-Z score of -13.23. This is a bad value and indicates that IBRX is not financially healthy and even has some risk of bankruptcy.
With a Altman-Z score value of -13.23, IBRX is not doing good in the industry: 78.52% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.23
ROIC/WACCN/A
WACC11.19%
IBRX Yearly LT Debt VS Equity VS FCFIBRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M -500M

2.3 Liquidity

A Current Ratio of 3.36 indicates that IBRX has no problem at all paying its short term obligations.
The Current ratio of IBRX (3.36) is worse than 61.27% of its industry peers.
IBRX has a Quick Ratio of 3.21. This indicates that IBRX is financially healthy and has no problem in meeting its short term obligations.
IBRX's Quick ratio of 3.21 is on the low side compared to the rest of the industry. IBRX is outperformed by 60.56% of its industry peers.
Industry RankSector Rank
Current Ratio 3.36
Quick Ratio 3.21
IBRX Yearly Current Assets VS Current LiabilitesIBRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M 500M

More info and screens

8

3. Growth

3.1 Past

IBRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.02%, which is quite impressive.
Looking at the last year, IBRX shows a very strong growth in Revenue. The Revenue has grown by 2274.40%.
The Revenue has been growing by 46.30% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)46.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.29%
Revenue 1Y (TTM)2274.4%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%5333.09%

3.2 Future

IBRX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 40.73% yearly.
The Revenue is expected to grow by 170.99% on average over the next years. This is a very strong growth
EPS Next Y15.56%
EPS Next 2Y19.88%
EPS Next 3Y28.63%
EPS Next 5Y40.73%
Revenue Next Year595.36%
Revenue Next 2Y328.11%
Revenue Next 3Y261.12%
Revenue Next 5Y170.99%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
IBRX Yearly Revenue VS EstimatesIBRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 2B 4B 6B 8B 10B
IBRX Yearly EPS VS EstimatesIBRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 2 -2 4 6 8 10

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

IBRX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IBRX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
IBRX Price Earnings VS Forward Price EarningsIBRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
IBRX Per share dataIBRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

A more expensive valuation may be justified as IBRX's earnings are expected to grow with 28.63% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.88%
EPS Next 3Y28.63%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for IBRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

IMMUNITYBIO INC

NASDAQ:IBRX (4/23/2025, 8:12:49 PM)

After market: 2.7 +0.01 (+0.37%)

2.69

0 (0%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-03 2025-03-03/bmo
Earnings (Next)05-08 2025-05-08/amc
Inst Owners11.38%
Inst Owner Change0.12%
Ins Owners5.38%
Ins Owner Change0.99%
Market Cap2.37B
Analysts83.64
Price Target11.48 (326.77%)
Short Float %19.34%
Short Ratio9.98
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)45.26%
Min EPS beat(2)34.64%
Max EPS beat(2)55.88%
EPS beat(4)2
Avg EPS beat(4)13.16%
Min EPS beat(4)-22.55%
Max EPS beat(4)55.88%
EPS beat(8)4
Avg EPS beat(8)-5.32%
EPS beat(12)5
Avg EPS beat(12)-8.01%
EPS beat(16)6
Avg EPS beat(16)-9.34%
Revenue beat(2)1
Avg Revenue beat(2)49.64%
Min Revenue beat(2)-5.28%
Max Revenue beat(2)104.56%
Revenue beat(4)2
Avg Revenue beat(4)24.22%
Min Revenue beat(4)-59.26%
Max Revenue beat(4)104.56%
Revenue beat(8)6
Avg Revenue beat(8)267.01%
Revenue beat(12)9
Avg Revenue beat(12)223.11%
Revenue beat(16)13
Avg Revenue beat(16)372.72%
PT rev (1m)-7.69%
PT rev (3m)-21.05%
EPS NQ rev (1m)-8.47%
EPS NQ rev (3m)80%
EPS NY rev (1m)24.63%
EPS NY rev (3m)25%
Revenue NQ rev (1m)-3.54%
Revenue NQ rev (3m)-8.03%
Revenue NY rev (1m)-15.46%
Revenue NY rev (3m)-24.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 160.89
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.61
EYN/A
EPS(NY)-0.52
Fwd EYN/A
FCF(TTM)-0.45
FCFYN/A
OCF(TTM)-0.44
OCFYN/A
SpS0.02
BVpS-0.55
TBVpS-0.57
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -108%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 100%
FCFM N/A
ROA(3y)-112.85%
ROA(5y)-102.54%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 39.24%
Cap/Sales 46.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.36
Quick Ratio 3.21
Altman-Z -13.23
F-Score4
WACC11.19%
ROIC/WACCN/A
Cap/Depr(3y)249.59%
Cap/Depr(5y)199.51%
Cap/Sales(3y)15458.8%
Cap/Sales(5y)10051.7%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)46.02%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%74.29%
EPS Next Y15.56%
EPS Next 2Y19.88%
EPS Next 3Y28.63%
EPS Next 5Y40.73%
Revenue 1Y (TTM)2274.4%
Revenue growth 3Y151.22%
Revenue growth 5Y46.3%
Sales Q2Q%5333.09%
Revenue Next Year595.36%
Revenue Next 2Y328.11%
Revenue Next 3Y261.12%
Revenue Next 5Y170.99%
EBIT growth 1Y4.76%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-0.2%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-6.67%
OCF growth 3YN/A
OCF growth 5YN/A